Management & Team
Our Management Team consists of proven, experienced leaders who are committed to focusing on People and on Therapies and Developing long-term relationships with our customers.
Dror Chevion is our Chief Executive Officer (CEO).
Mr. Chevion is a successful Serial Entrepreneur with over 25 years of global experience in several industries. Earlier in his career, Mr. Chevion completed his BA in economics and business at the Hebrew University, Jerusalem and then began working for the Israeli Ministry of Finance, Department of the Budget. Mr. Chevion then continued to the private sector where he has held executive positions including VP Finance, VP Business Development, CEO, Managing Director, and Board Member. In addition, Mr. Chevion has served as Board Member in 2 publicly traded companies on the Tel-Aviv Stock Exchange. Mr. Chevion has an MBA from a joint program by J. L. Kellogg School of Management (Chicago, USA) and the Tel-Aviv University (Israel).
Prof. Mordechai (Mottie) Chevion is our Chief Scientific Officer (CSO).
Mordechai “Mottie” Chevion, professor of biochemistry and incumbent of the Dr. William Ganz Chair of Heart Studies, has formal university training in Chemistry and Physics (B.Sc.), Physical Chemistry (M.Sc.), and Pharmaceutical Chemistry (Ph.D.). His past research projects have focused on the mechanism of food-induced hemolytic crisis in G-6-PD deficiency (Favism), and the role of transition metals in biologically injurious processes involving free radicals. Prof. Chevion has also investigated the burn related injurious processes induced to the skin and eye tissues by toxic chemicals including warfare agents. Recently he focused on novel mechanisms of protection of the ischemic heart, brain, retina and intestine. These studies have been extended to the diabetic heart.
Through his research, Prof. Chevion has developed new drugs—currently being developed for clinical application—and novel modalities to counteract tissue injury mediated by free radicals. These drugs proved highly effective against inflammatory and other diseases.
Over the years, Prof. Chevion has edited and published two books, over one hundred and sixty fully refereed scientific papers, more than 400 abstracts and short papers, and invented 10 patents concerning antioxidant drugs.
In addition to his intensive academic activities, Prof. Chevion has been involved in establishing pioneering relationships and promoting cooperative activities with foreign (mainly Asian) governments, universities and research institutions. For his successful activities, Prof. Chevion was nominated for the King Boudoin International Development Prize in 1994. Prof. Chevion served as a consultant for the major corporations in Israel and other countries.
Prof. Amir Elami, M.D., is our Chief Medical Officer (CMO)
Dr. Elami, graduated from the Hebrew University - Hadassah School of Medicine, Jerusalem, Israel.
He completed residency in General and Cardiothoracic (CT) Surgery in Haifa, and advanced training (fellowship) in the repair of congenital heart malformations and in heart transplantation at UCLA medical center, Los Angeles, Ca. Dr. Elami was the Acting Director of the Department of Cardiothoracic Surgery at Hadassah Medical Center, and later the Director and Head of CT Surgery at Lady Davis Carmel Medical Center in Haifa.
Dr. Elami is a Clinical Associate Professor at the Hebrew University Faculty of Medicine. His clinical research involved unique solutions for the surgical repair of valvular heart disease and congenital defects and coronary artery disease. He also took part in the research of organ cryopreservation for future transplantation.
Dr. Elami was one of the founders of a startup company, CorAssist, and the principal investigator (PI) in the development of an innovative device for the treatment of diastolic heart failure. He performed the pre-clinical experiments for another startup company, Mitrassist, developing an implantable mitral prosthesis designed for future trans-catheter deployment.
Dr. Elami took part as the PI in multicenter trials testing the safety and efficacy of Parecoxib/Valdecoxib in patients undergoing CABG, and testing the potential for reduction of cognitive impairment using Dexanabinol in subjects undergoing CABG. He also served as the surgical PI in large multicenter, multinational trials in coronary surgery, among which was studying the optimal revascularization strategy in diabetic patients with multivessel disease (Freedom Trial).
Dr. Susan Alpert, M.D., Ph.D. is our Regulatory Lead.
Dr. Alpert has served as Executive Vice President of Regulatory Affairs, Exalenz Bioscience Ltd, Senior Advisor at Accelmed Fund. She served as Regulatory Consultant and Chief Regulatory Officer at Accelmed Fund. She serves as a Member of the Scientific Advisory Team at Cellect Biomed Ltd. Dr. Alpert serves as an Advisor of VGBio, Inc. She is Executive in Residence at the Medical Industry Leadership Institute at the Carlson School at the University of MN. She served as Executive Vice President of Regulatory Affairs at Exalenz Bioscience Ltd and served as its Senior Vice President of Regulatory Affairs since November 2011. Dr. Alpert served as Chief Quality & Regulatory Officer and Vice President at Medtronic MiniMed, Inc. since May 2004. She served as Chief Regulatory Officer of Medtronic plc since May 2008 and its Senior Vice President of Global Regulatory Affairs/Senior Vice President from November 2005 to May 2011. Dr. Alpert was responsible for all Medtronic quality, regulatory, and clinical compliance efforts including overseeing health policy and payment. She served as Chief Quality & Regulatory Officer of Medtronic from May 2004 to November 2005 and as its Vice President from July 2003 to November 2005. She joined Medtronic in July 2003. She served as Vice President of Regulatory Sciences at CR Bard Inc. from October 2000 to July 2003 and also served as its Senior Vice President of Regulatory. Before joining Bard, Dr. Alpert served at the FDA where she held a variety of positions in the Centers dealing with drugs, devices, and radiological health, and foods from June 1987 to August 2000, including six years as the Director of the Office of Device Evaluation. She serves on the board of the Food Drug Law Institute (FDLI). Dr. Alpert is a Director of the Medical Technology Leadership Forum (MTLF). In addition, she is a Director of the Women Business Leaders (WBL). She has served as the Director of Medical Device Assessment in the FDA. She is a microbiologist and pediatrician with a specialty in infectious diseases and has practical experience in laboratory research and clinical trials. Dr. Alpert holds an M.S. and Ph.D. in Biomedical Sciences from New York University. She received her M.D. from the University of Miami and completed her clinical training at Montefiore Medical Center and at Children's National Medical Center. She completed her undergraduate degree at Barnard College, Columbia University.
Dr. Vladimir Vinokur MRSB – Senior Investigator, Head of Biology.
Dr. Vinokur received his B.Sc. degree in Biochemistry and Molecular Biology from Ben Gurion University in Negev and his M.Sc. and Ph.D. degrees in Biomedical Sciences from The Hebrew University of Jerusalem. He has been working with Prof. Chevion for over 15 years, and was extensively involved in the experimental studies of animal models of various human pathologies, including Type 2 Diabetes, and the development of drugs targeted to treat these disorders. During these years Dr. Vinokur took part in several scientific projects. Dr. Vinokur served as a visiting researcher in The Hatter Institute for Cardiovascular Research in University College, London, and has several publications in peer-reviewed journals and presentations in international scientific meetings.
During the recent period the core team, including Dr. Vinokur, has been working diligently on preparing the company for fund-raising and executing its strategy – from understanding the IP rights and preparing an IP strategy; understanding the markets for the company’s product, making contacts with potential cooperating companies (large pharmaceutical companies in Israel and all over the world), interacting with the regulatory agencies, and preparing and submitting IND Application following pre-IND discussions; working with legal consultants; participating in relevant international conferences and presenting our findings/plans; applying for and winning international competitions for innovations, etc.